Adaptive Biotechnologies to Present Data from Largest Study to Date Demonstrating Superior Sensitivity and Prognostic Value of Next-Generation Sequencing-Based Minimal Residual Disease (MRD)Detection in Pediatric Acute Lymphoblastic Leukemia

Adaptive Biotechnologies, the leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors, will present data from a study of more than 400 children with acute lymphoblastic leukemia (ALL), some observed for more than a decade, demonstrating that the company’s immunosequencing platform, available clinically in the United States as the clonoSEQ® Process, can more sensitively detect minimal residual disease (MRD) than flow cytometry, and that MRD detected using this method is predictive of a patient’s ultimate outcome. These data and more will be presented at the 20th Congress of the European Hematology Association in Vienna, Austria, June 11-14, 2015.

“This study demonstrates that low level MRD, which is readily detectable by the high sensitivity of next-generation sequencing, has a significant negative impact on survival for children with ALL,” says Dr. Harlan Robins, Chief Scientific Officer and Co-Founder of Adaptive Biotechnologies.

During EHA, data will also be presented from research studies using Adaptive’s immunosequencing platform to monitor the immune reconstitution in patients who have received cord blood transplants. These studies show how T-cell diversity at earlier time points post-transplant can be used to determine whether patients are at risk of infection early on, which could be useful for physicians in determining the course of care.

In addition, data will be presented utilizing immunosequencing that provide insight into the biology of different subgroups of patients with Diffuse Large B-cell Lymphoma (DLBCL) that may have implications for risk stratification and patient treatment decisions.

Representatives from Adaptive Biotechnologies will be exhibiting at EHA booth #1304 to answer questions about its immunosequencing technology.

Oral Presentation:

Abstract No. S438: High throughput sequencing as a measure of early response to therapy in childhood ALL
Presenter: Lanny Kirsch
Presentation Time: Saturday, June 13, 12:00-12:15 p.m.
Location: Room C1

Poster Presentations:

Abstract No. P332: Defining immunoglobulin somatic hypermutation in de novo diffuse large B-cell lymphoma patients: potential application for prognosis and risk stratification
Presenter: Lanny Kirsch
Poster Session: Friday, June 12, 5:15-6:45 p.m.
Location: Poster Area Hall C

Abstract No. P349: TCR repertoire diversity assessed with Immunosequencing is associated with patient mortality following cord blood transplant
Presenter: Ryan Emerson
Poster Session: Friday, June 12, 5:15-6:45 p.m.
Location: Poster Area Hall C

E-Posters:

Abstract No. E855: TRD/TRA rearrangements occur infrequently in early thymic precursor subtype of T lymphoblastic leukemia by high-throughput sequencing
Author: Anna Sherwood
Available: June 12-13, 2015

Abstract No. E998: High-throughput sequencing of both immunoglobulin light and heavy chain gene rearrangements improves detection of neoplastic clones in mature B-cell lymphomas
Author: Anna Sherwood
Available: June 12-13, 2015

Abstract No. E974: High throughput TCR sequencing provides added value in the diagnosis of cutaneous T-cell lymphoma
Author: Lanny Kirsch
Available: June 12-13, 2015

About Adaptive Biotechnologies®

Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.

About immunoSEQ®

Adaptive helps researchers make discoveries in oncology, autoimmune disorders and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology under the immunoSEQ brand name. The immunoSEQ Kit for research use only is now available to facilitate the integration of immunosequencing into research centers. The immunoSEQ Assay is not for use in diagnostic procedures.

About clonoSEQ®

Adaptive’s clonoSEQ Process enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as an aid to clinical decision making for patients with lymphoid cancers (blood cancers). With its ability to detect cancer cells at a level as low as one per one million white blood cells, the clonoSEQ MRD Test is one to two orders of magnitude more sensitive than the other methods of MRD detection, such as ASO-PCR and flow cytometry. The clonoSEQ Process was previously marketed as the ClonoSIGHT™ process by Sequenta, Inc., which was acquired by Adaptive Biotechnologies in January 2015.

The company is also validating a second novel oncology diagnostic to quantify the presence and clonality of Tumor Infiltrating Lymphocytes (TILs) and to create a reliable measure of “immunocompetency” to predict or monitor response to cancer treatments that directly alter the host immune system.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150611006433/en/